1883333-57-0
Chemical Structure
Glycyl-Exatecan TFA
Synonym(s): Glycyl-DX-8951 TFA; Exatecan analog 2 TFA
- CAS No.: 1883333-57-0
- Formula:C28H26F4N4O7
- Molecular Weight:606.52
IUPAC Name: 2-amino-N-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)acetamide 2,2,2-trifluoroacetate
InChIKey: GRCHONWRLMRUAI-AUMQKKOASA-N
SMILES: O=C(N[C@H]1CCC2=C3C1=C(CN4C(C(COC([C@@]5(CC)O)=O)=C5C=C46)=O)C6=NC3=CC(F)=C2C)CN.O=C(O)C(F)(F)F
Biological Activity: Glycyl-Exatecan TFA (G-DX-8951 TFA) is a Topoisomerase I inhibitor. Glycyl-Exatecan TFA exhibits weaker in vitro cytotoxicity than DX-8951 (HY-13631), and can further release DX-8951 in vivo. Glycyl-Exatecan TFA can be used in studies related to Exatecan metabolism and antitumor drug delivery[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Glycyl-Exatecan TFA | 98.73% | Glycyl-Exatecan TFA (G-DX-8951 TFA) is a Topoisomerase I inhibitor. Glycyl-Exatecan TFA exhibits weaker in vitro cytotoxicity than DX-8951 (HY-13631), and can further release DX-8951 in vivo. Glycyl-Exatecan TFA can be used in studies related to Exatecan metabolism and antitumor drug delivery. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glycyl-Exatecan-d5 hydrochloride | 98.97% | Glycyl-Exatecan-d5 (Glycyl-DX-8951-d5) hydrochloride is deuterium labeled Glycyl-Exatecan (HY-128995A). Glycyl-Exatecan (Glycyl-DX-8951), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan has significantly antitumor activity. Glycyl-Exatecan can be used for cancers like solid tumors research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Wente MN, et al. DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors. Investigational new drugs. 2005 Aug;23(4):339-47. [Content Brief]
- [2]. Masubuchi N. Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice. Pharmazie. 2004;59:374-377.
